• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·YATHARTH.BO
Share

Yatharth Hospital & Trauma Care Services Limited Stocks

₹ 826.15Last Updated 11.06.2026

Issuer Rating

4/7
Performance

Average

Risk

Moderate

Recommendation

Hold

Market Cap

₹ 847.72M

₹ 826.15
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 2008 and headquartered in Noida, India, Yatharth Hospital & Trauma Care Services Limited operates and manages super-specialty medical facilities across Delhi and Madhya Pradesh. These hospitals offer an extensive range of healthcare services. Core specializations include women's health (gynecology), digestive medicine (gastroenterology), respiratory conditions (pulmonology), pediatrics, kidney and urinary tract care (nephrology and urology), cardiology, orthopedics, spine and rheumatology, and neurosciences. Additionally, the company provides general medicine, surgery, ENT, physiotherapy, rehabilitation, interventional spine and pain medicine, nutrition, pathology, laboratory diagnostics, dentistry, ophthalmology, dermatology, anesthesiology, radiology, and psychology and psychiatry.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on E

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of YATHARTH.BO is 990 and suggests 19% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.06.2026 01:34

Rally ahead of SpaceX debut: best day since April for S&P 500 and Nasdaq, oil down 5%

12.06.2026 01:01

SpaceX holds record IPO: Elon Musk's space company raises $75 billion

12.06.2026 00:55

Google discusses producing part of its new AI chip at Samsung factories. Is this a threat to TSMC?

12.06.2026 00:10

BofA raised its rating on Intel stock by two notches at once. What is the bank betting on?

11.06.2026 22:46

Trump canceled planned new strikes on Iran. Oil below $90 per barrel

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026